Education
About Us
Working with TipRanks
Follow Us
Nurix Therapeutics (NRIX)
NASDAQ:NRIX
Total Valuation
Nurix Therapeutics has a market cap or net worth of $1.72B. The enterprise value is $1.26B.
Market Cap$1.72B
Enterprise Value$1.26B
Share Statistics
Nurix Therapeutics has 102,843,010 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding102,843,010
Owned by Insiders4.87%
Owned by Institutions0.20%
Financial Efficiency
Nurix Therapeutics’s return on equity (ROE) is -0.49 and return on invested capital (ROIC) is -47.26%.
Return on Equity (ROE)-0.49
Return on Assets (ROA)-0.38
Return on Invested Capital (ROIC)-47.26%
Return on Capital Employed (ROCE)-0.47
Revenue Per Employee293.64K
Profits Per Employee-924.67K
Employee Count286
Asset Turnover0.12
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Nurix Therapeutics is ―. Nurix Therapeutics’s PEG ratio is -0.94.
PE Ratio―
PS Ratio17.45
PB Ratio2.72
Price to Fair Value2.72
Price to FCF-5.56
Price to Operating Cash Flow-6.27
PEG Ratio-0.94
Income Statement
In the last 12 months, Nurix Therapeutics had revenue of 83.98M and earned -264.46M in profits. Earnings per share was -3.05.
Revenue83.98M
Gross Profit65.12M
Operating Income-285.67M
Pretax Income-263.70M
Net Income-264.46M
EBITDA-244.84M
Earnings Per Share (EPS)-3.05
Cash Flow
In the last 12 months, operating cash flow was -249.47M and capital expenditures -14.00M, giving a free cash flow of -263.47M billion.
Operating Cash Flow-249.47M
Free Cash Flow-263.47M
Free Cash Flow per Share-2.56
Dividends & Yields
Nurix Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.48
52-Week Price Change-2.39%
50-Day Moving Average18.32
200-Day Moving Average12.81
Relative Strength Index (RSI)43.08
Average Volume (3m)1.16M
Important Dates
Nurix Therapeutics upcoming earnings date is Apr 14, 2026, After Close (Confirmed).
Last Earnings DateJan 28, 2026
Next Earnings DateApr 14, 2026
Ex-Dividend Date―
Financial Position
Nurix Therapeutics as a current ratio of 7.02, with Debt / Equity ratio of 10.34%
Current Ratio7.02
Quick Ratio7.02
Debt to Market Cap0.00
Net Debt to EBITDA0.78
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Nurix Therapeutics has paid 760.00K in taxes.
Income Tax760.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Nurix Therapeutics EV to EBITDA ratio is -5.20, with an EV/FCF ratio of -4.84.
EV to Sales15.17
EV to EBITDA-5.20
EV to Free Cash Flow-4.84
EV to Operating Cash Flow-5.11
Balance Sheet
Nurix Therapeutics has $592.94M in cash and marketable securities with $55.73M in debt, giving a net cash position of $537.21M billion.
Cash & Marketable Securities$592.94M
Total Debt$55.73M
Net Cash$537.21M
Net Cash Per Share$5.22
Tangible Book Value Per Share$6.22
Margins
Gross margin is -87.41%, with operating margin of -340.16%, and net profit margin of -314.90%.
Gross Margin-87.41%
Operating Margin-340.16%
Pretax Margin-314.00%
Net Profit Margin-314.90%
EBITDA Margin-291.55%
EBIT Margin-314.00%
Analyst Forecast
The average price target for Nurix Therapeutics is $31.08, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$31.08
Price Target Upside86.00% Upside
Analyst ConsensusStrong Buy
Analyst Count13
Revenue Growth Forecast48.32%
EPS Growth Forecast-1.91%